Literature DB >> 21123823

Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.

Tim H-P Chen1, Amal Kambal, Kilannin Krysiak, Mark A Walshauser, Gagan Raju, Justin F Tibbitts, Matthew J Walter.   

Abstract

Heterozygous deletions spanning chromosome 5q31.2 occur frequently in the myelodysplastic syndromes (MDS) and are highly associated with progression to acute myeloid leukemia (AML) when p53 is mutated. Mutagenesis screens in zebrafish and mice identified Hspa9 as a del(5q31.2) candidate gene that may contribute to MDS and AML pathogenesis, respectively. To test whether HSPA9 haploinsufficiency recapitulates the features of ineffective hematopoiesis observed in MDS, we knocked down the expression of HSPA9 in primary human hematopoietic cells and in a murine bone marrow-transplantation model using lentivirally mediated gene silencing. Knockdown of HSPA9 in human cells significantly delayed the maturation of erythroid precursors, but not myeloid or megakaryocytic precursors, and suppressed cell growth by 6-fold secondary to an increase in apoptosis and a decrease in the cycling of cells compared with control cells. Erythroid precursors, B lymphocytes, and the bone marrow progenitors c-kit(+)/lineage(-)/Sca-1(+) (KLS) and megakaryocyte/erythrocyte progenitor (MEP) were significantly reduced in a murine Hspa9-knockdown model. These abnormalities suggest that cooperating gene mutations are necessary for del(5q31.2) MDS cells to gain clonal dominance in the bone marrow. Our results demonstrate that Hspa9 haploinsufficiency alters the hematopoietic progenitor pool in mice and contributes to abnormal hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123823      PMCID: PMC3056590          DOI: 10.1182/blood-2010-06-293167

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

Authors:  Jacqueline Boultwood; Carrie Fidler; Amanda J Strickson; Fiona Watkins; Susana Gama; Lyndal Kearney; Sabrina Tosi; Arek Kasprzyk; Jan-Fang Cheng; Rina J Jaju; James S Wainscoat
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

2.  Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha.

Authors:  Matthew J Walter; John S Park; Rhonda E Ries; Steven K M Lau; Michael McLellan; Sara Jaeger; Richard K Wilson; Elaine R Mardis; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-19       Impact factor: 11.205

3.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Authors:  Sonali M Smith; Michelle M Le Beau; Dezheng Huo; Theodore Karrison; Ronald M Sobecks; John Anastasi; James W Vardiman; Janet D Rowley; Richard A Larson
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

4.  Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome.

Authors:  Sarah E Craven; Dorothy French; Weilan Ye; Frederic de Sauvage; Arnon Rosenthal
Journal:  Blood       Date:  2005-01-13       Impact factor: 22.113

5.  Site-specific deletions of the mitochondrial genome in the Pearson marrow-pancreas syndrome.

Authors:  A Rötig; V Cormier; F Koll; C E Mize; J M Saudubray; A Veerman; H A Pearson; A Munnich
Journal:  Genomics       Date:  1991-06       Impact factor: 5.736

6.  Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.

Authors:  N Mauritzson; M Albin; L Rylander; R Billström; T Ahlgren; Z Mikoczy; J Björk; U Strömberg; P G Nilsson; F Mitelman; L Hagmar; B Johansson
Journal:  Leukemia       Date:  2002-12       Impact factor: 11.528

7.  NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Authors:  Carrie Fidler; Fiona Watkins; David T Bowen; Timothy J Littlewood; James S Wainscoat; Jacqueline Boultwood
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

8.  Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member.

Authors:  R Wadhwa; S Takano; M Robert; A Yoshida; H Nomura; R R Reddel; Y Mitsui; S C Kaul
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

9.  Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration.

Authors:  Toshiyuki Araki; Yo Sasaki; Jeffrey Milbrandt
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

10.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

View more
  20 in total

1.  The DNLZ/HEP zinc-binding subdomain is critical for regulation of the mitochondrial chaperone HSPA9.

Authors:  Michael T Vu; Peng Zhai; Juhye Lee; Cecilia Guerra; Shirley Liu; Michael C Gustin; Jonathan J Silberg
Journal:  Protein Sci       Date:  2012-01-04       Impact factor: 6.725

Review 2.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 3.  Myelodysplastic syndromes.

Authors:  Olatoyosi Odenike; John Anastasi; Michelle M Le Beau
Journal:  Clin Lab Med       Date:  2011-10-10       Impact factor: 1.935

4.  Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells.

Authors:  Kilannin Krysiak; Justin F Tibbitts; Jin Shao; Tuoen Liu; Matthew Ndonwi; Matthew J Walter
Journal:  Exp Hematol       Date:  2014-12-27       Impact factor: 3.084

Review 5.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.

Authors:  Adam S Sperling; Christopher J Gibson; Benjamin L Ebert
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

6.  Regulation of human Nfu activity in Fe-S cluster delivery-characterization of the interaction between Nfu and the HSPA9/Hsc20 chaperone complex.

Authors:  Christine Wachnowsky; Yushi Liu; Taejin Yoon; J A Cowan
Journal:  FEBS J       Date:  2017-12-29       Impact factor: 5.542

7.  Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9.

Authors:  Klaus Schmitz-Abe; Szymon J Ciesielski; Paul J Schmidt; Dean R Campagna; Fedik Rahimov; Brenda A Schilke; Marloes Cuijpers; Klaus Rieneck; Birgitte Lausen; Michael L Linenberger; Anoop K Sendamarai; Chaoshe Guo; Inga Hofmann; Peter E Newburger; Dana Matthews; Akiko Shimamura; Pieter J L M Snijders; Meghan C Towne; Charlotte M Niemeyer; Henry G Watson; Morten H Dziegiel; Matthew M Heeney; Alison May; Sylvia S Bottomley; Dorine W Swinkels; Kyriacos Markianos; Elizabeth A Craig; Mark D Fleming
Journal:  Blood       Date:  2015-10-21       Impact factor: 22.113

Review 8.  Role of heat shock proteins in stem cell behavior.

Authors:  Guo-Chang Fan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

9.  Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Authors:  Rebekka K Schneider; Vera Ademà; Dirk Heckl; Marcus Järås; Mar Mallo; Allegra M Lord; Lisa P Chu; Marie E McConkey; Rafael Kramann; Ann Mullally; Rafael Bejar; Francesc Solé; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2014-09-18       Impact factor: 31.743

10.  The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.

Authors:  D Ronchetti; K Todoerti; G Tuana; L Agnelli; L Mosca; M Lionetti; S Fabris; P Colapietro; M Miozzo; M Ferrarini; P Tassone; A Neri
Journal:  Blood Cancer J       Date:  2012-11-23       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.